A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

E Van den Neste, M Andre, G Thomas, A Stamatoullas, C Haioun, A Belhabri, O Reman, O Casasnovas, H Ghesquieres, G Verhoef, Marie-José Claessen, HA Poirel, MC Copin, R Dubois, P Vandenberghe, IA Stoian, AS Cottereau, S Bailly, L Knoops, F Morschhauser

Research output: Contribution to journalArticleAcademicpeer-review

43 Citations (Scopus)
19 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)840-848
Number of pages9
Issue number5
Publication statusPublished - 2018

Research programs

  • EMC OR-01

Cite this